Product nameAnti-Epstein-Barr Virus IgG Avidity ELISA kit (VCA)
See all IgG kits
Sample typeSerum, Heparin Plasma, Citrate Plasma
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
The Anti-Epstein-Barr Virus IgG ELISA (Enzyme-Linked Immunosorbent Assay) kit (VCA) (ab222940) is designed for the qualitative determination of Epstein-Barr virus viral capsid (VCA)-specific IgG avidity in human serum or plasma (citrate, heparin) to differentiate between acute and past infection. This kit can be used with Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) (ab108730).
Microplates are coated with specific antigens to bind the corresponding antibodies of the sample (dual pipetting). After washing the wells to remove all unbound sample material, one well is incubated with reagent and the corresponding well with washing buffer. The reagent removes the low-avidity antibodies from the antigens whereas the high-avidity ones are still bound to the specific antigens. After a second washing step to remove the rest of reagent and low-avidity antibodies, a horseradish peroxidase (HRP) labeled conjugate is added. This conjugate binds to the captured antibodies. In a third washing step unbound conjugate is removed. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product.
The intensity of this product is proportional to the amount of specific antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint color.
Absorbance at 450/620 nm is read using an ELISA microwell plate reader.
The presence of IgG antibodies to Epstein-Barr Virus indicates the occurrence of the infection but does not distinguish between recent and past infection. Specific IgM antibodies are first detected approximately in ten days and peak at about four weeks post infection. They may persist for several months after acute infections. Based on the evidence that antibody avidity gradually increases after exposure to an immunogen, avidity of IgG antibodies can be used as a marker for distinguishing recent primary from long-term infections. Avidity describes the binding strength of a specific antibody to its antigen. Low-avidity IgG antibodies indicate a primary infection, whereas the presence of IgG antibodies with high avidity points to persistency or reactivation of infection.
Tested applicationsSuitable for: Indirect ELISAmore details
PlatformPre-coated microplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests Bottle 1 unit Epstein-Barr Virus (VCA) IgG Control High 1 x 2ml Epstein-Barr Virus (VCA) IgG Control Low 1 x 2ml Reagent 1 x 15ml
- Ig gamma 1 chain C region
- Ig gamma 2 chain C region
- Ig gamma 3 chain C region
Our Abpromise guarantee covers the use of ab222940 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Indirect ELISA||Use at an assay dependent concentration.|
ab222940 has not yet been referenced specifically in any publications.